Literature DB >> 30235570

Adaptive Design: Results of 2012 Survey on Perception and Use.

Caroline Claire Morgan1, Susan Huyck2, Martin Jenkins3, Li Chen4, Alun Bedding5, Christopher S Coffey6, Brenda Gaydos7, J Kyle Wathen8.   

Abstract

Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG Survey Subteam has collected data on the usage of adaptive designs in clinical research from multiple sources, including a recent ADSWG survey regarding the perception and usage of adaptive designs in academia and industry for studies between 2008 and 2011, as well as barriers to usage; a literature review examining publications of adaptive design methodology and usage between 2000 and 2011; and a trial registry review of adaptive design references from 1996 to 2011. The comprehensive results of the ADSWG 2012 survey are provided in this article with comparisons to our previous 2008 survey, the literature and registry reviews, and recent surveys carried out by the US Food and Drug Administration (FDA) and the European Medicines Agency. Results of the ADSWG 2012 survey illustrate that industry and academia are showing more enthusiasm for adaptive trials, accompanied by an increase in the number of trials using designs described as less well understood in the FDA draft guidance on adaptive designs, published in 2010. The increased use of these methods in exploratory trials is consistent with the FDA draft guidance. The survey also identified several examples of successful marketing applications supported by confirmatory trials utilizing adaptive designs that were considered, at least at the time of the draft guidance, as less well understood. While some of the technological barriers to adaptive design usage identified in the 2008 survey are now less common, there are several important persistent barriers to usage. Organizations can help overcome these barriers through education, preplanning, and early engagement in discussions with the regulators.

Keywords:  adaptive design; early stopping; interim analysis; sample size reestimation; treatment selection

Year:  2014        PMID: 30235570     DOI: 10.1177/2168479014522468

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  18 in total

1.  Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.

Authors:  Timothy C Guetterman; Michael D Fetters; Laurie J Legocki; Samkeliso Mawocha; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Res Regul Aff       Date:  2015-09-18

2.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

3.  A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network.

Authors:  Samkeliso C Mawocha; Michael D Fetters; Laurie J Legocki; Timothy C Guetterman; Shirley Frederiksen; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Trials       Date:  2017-01-31       Impact factor: 2.486

4.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

Review 5.  Current usage and challenges of master protocols-based on survey results by ASA BIOP oncology methodology working group master protocol sub-team.

Authors:  Xiaoyun Li; Chengxing Lu; Kristine Broglio; Paul Bycott; Jie Chen; Qi Jiang; Jianchang Lin; Jingjing Ye; Jun Yin
Journal:  Ann Transl Med       Date:  2022-09

6.  Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

Authors:  Merit Cudkowicz; Marianne K Chase; Christopher S Coffey; Dixie J Ecklund; Brenda J Thornell; Codrin Lungu; Katy Mahoney; Laurie Gutmann; Jeremy M Shefner; Kevin J Staley; Michael Bosch; Eric Foster; Jeffrey D Long; Emine O Bayman; James Torner; Jon Yankey; Richard Peters; Trevis Huff; Robin A Conwit; Shlomo Shinnar; Donna Patch; Basil T Darras; Audrey Ellis; Roger J Packer; Karen S Marder; Claudia A Chiriboga; Claire Henchcliffe; Joyce Ann Moran; Blagovest Nikolov; Stewart A Factor; Carole Seeley; Steven M Greenberg; Anthony A Amato; Sara DeGregorio; Tanya Simuni; Tina Ward; John T Kissel; Stephen J Kolb; Amy Bartlett; Joseph F Quinn; Kellie Keith; Steven R Levine; Nadege Gilles; Patricia K Coyle; Jessica Lamb; Gil I Wolfe; Annemarie Crumlish; Luis Mejico; Muhammad Maaz Iqbal; James D Bowen; Caryl Tongco; Louis B Nabors; Khurram Bashir; Melanie Benge; Craig M McDonald; Erik K Henricson; Björn Oskarsson; Bruce H Dobkin; Catherine Canamar; Tracy A Glauser; Daniel Woo; Angela Molloy; Peggy Clark; Timothy L Vollmer; Alexander J Stein; Richard J Barohn; Mazen M Dimachkie; Jean-Baptiste Le Pichon; Michael G Benatar; Julie Steele; Lawrence Wechsler; Paula R Clemens; Christine Amity; Robert G Holloway; Christine Annis; Mark P Goldberg; Mariam Andersen; Susan T Iannaccone; A Gordon Smith; J Robinson Singleton; Mariana Doudova; E Clarke Haley; Mark S Quigg; Stephanie Lowenhaupt; Beth A Malow; Karen Adkins; David B Clifford; Mengesha A Teshome; Noreen Connolly
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 7.  Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.

Authors:  Amelie Elsäßer; Jan Regnstrom; Thorsten Vetter; Franz Koenig; Robert James Hemmings; Martina Greco; Marisa Papaluca-Amati; Martin Posch
Journal:  Trials       Date:  2014-10-02       Impact factor: 2.279

8.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

9.  Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials.

Authors:  Munyaradzi Dimairo; Jonathan Boote; Steven A Julious; Jonathan P Nicholl; Susan Todd
Journal:  Trials       Date:  2015-09-28       Impact factor: 2.279

Review 10.  Adaptive designs undertaken in clinical research: a review of registered clinical trials.

Authors:  Isabella Hatfield; Annabel Allison; Laura Flight; Steven A Julious; Munyaradzi Dimairo
Journal:  Trials       Date:  2016-03-19       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.